Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.

Cancer letters - 28 Mar 2010

Zimmer Yitzhak, Vaseva Angelina V, Medová Michaela, Streit Bruno, Blank-Liss Wieslawa, Greiner Richard H, Schiering Nikolaus, Aebersold Daniel M

Abstract excerpt

Point mutations emerge as one of the rate-limiting steps in tumor response to small molecule inhibitors of protein kinases. Here we characterized the response of the MET mutated variants, V1110I, V1238I, V1206L and H1112L to the small molecule SU11274. Our results reveal a distinct inhibition pat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mitogen-Activated Protein Kinase 3
Share to NIH 3T3 Cells
Share to Oncogene Protein v-akt

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phospholipase C gamma

Share to Proto-Oncogene Proteins c-met

Share to STAT3 Transcription Factor

Share to Sulfonamides

Share to Wound Healing

Source

Identifiers

PMID: 19783361
DOI: 10.1016/j.canlet.2009.08.017

Genes

MET
STAT3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19783361-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.PMID 19783361Read ↗

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.Semantic proximity Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy.Semantic proximity Read ↗

Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.Semantic proximity Read ↗

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.Semantic proximity Read ↗

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.Semantic proximity Read ↗

Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.Semantic proximity Read ↗

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Semantic proximity Read ↗

In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.Semantic proximity Read ↗

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity <i>in vivo</i>Semantic proximity Read ↗

A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer PatientsSemantic proximity Read ↗

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.